Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCK trial of nivolumab monotherapy in rare dMMR/MSI-high tumors
jRCT2091220344Phase 2Completed
- Sponsor
- National Cancer Center Hospital
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in rare cancer, Nonhematologic neoplasms and microsatellite instability-high cancer, sponsored by National Cancer Center Hospital. Primary endpoint: Objective response rate. Started Apr 2018; status: completed.
02
Drugs
03
Conditions
rare cancerNonhematologic neoplasmsmicrosatellite instability-high cancer
Beyond the preview
Go deeper on jRCT2091220344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220344.